Timothy Furnish

Timothy Furnish

Auto-generated profile, based on publicly available information

Timothy Furnish

Department of Anesthesiology, Division of Pain Medicine, University of California San Diego , San Diego, CA 92037

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2019 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
RGRodney A. Gabriel
Rodney A. Gabriel
MSMatthew W. Swisher
Matthew W. Swisher
JSJacklynn F. Sztain
Jacklynn F. Sztain
TFTimothy J. Furnish
Timothy J. Furnish
BIBrian M. Ilfeld
Brian M. Ilfeld
ESEngy T. Said
Engy T. Said
Introduction: There are various important implications associated with poorly controlled postoperative pain in the adult surgical patient – this includes cardiopulmonary complications, opioid-related side effects, unplanned hospital admissions, prolonged hospital stay, and the subsequent development of chronic pain or opioid addiction. With the ongoing national opioid crisis, it is imperative that perioperative providers implement pathways for surgical patients that reduce opioid requirements and pain-related complications. Areas covered: In this review, the authors discuss the components of a multimodal opioid-sparing analgesia pathway as it pertains to the perioperative environment. Medications reviewed include gabapentinoids, acetaminophen, non-steroidal anti-inflammatory drugs, ketamine, intravenous lidocaine, dexmedetomidine, and glucocorticoids. The use of peripheral nerve blocks and neuraxial analgesia are also discussed. Expert opinion: In appropriate cases, regional anesthetic interventions are extremely useful for postoperative analgesia, including peripheral nerve blocks and neuraxial analgesia and while newer postoperative analgesics have been postulated, the literature on such is presently controversial. Coordinated approaches to pain management are recommended to reduce the need for opioids and to improve patient satisfaction post-surgery.

4 May 2020 in Regional Anesthesia & Pain Medicine
Verified
Journal Article
Closed access
PDF file
JCJoel P Castellanos
Joel P Castellanos
CWChris Woolley
Chris Woolley
KBKelly Amanda Bruno
Kelly Amanda Bruno
FZFadel Zeidan
Fadel Zeidan
AHAdam Halberstadt
Adam Halberstadt
TFTimothy Furnish
Timothy Furnish
The development of chronic pain is a complex mechanism that is still not fully understood. Multiple somatic and visceral afferent pain signals, when experienced over time, cause a strengthening of certain neural circuitry through peripheral and central sensitization, resulting in the physical and emotional perceptual chronic pain experience. The mind-altering qualities of psychedelics have been attributed, through serotonin 2A (5-HT2A) receptor agonism, to ‘reset’ areas of functional connectivity (FC) in the brain that play prominent roles in many central neuropathic states. Psychedelic substances have a generally favorable safety profile, especially when compared with opioid analgesics. Clinical evidence to date for their use for chronic pain is limited; however, several studies and reports over the past 50 years have shown potential analgesic benefit in cancer pain, phantom limb pain and cluster headache. While the mechanisms by which the classic psychedelics may provide analgesia are not clear, several possibilities exist given the similarity between 5-HT2A activation pathways of psychedelics and the nociceptive modulation pathways in humans. Additionally, the alterations in FC seen with psychedelic use suggest a way that these agents could help reverse the changes in neural connections seen in chronic pain states. Given the current state of the opioid epidemic and limited efficacy of non-opioid analgesics, it is time to consider further research on psychedelics as analgesics in order to improve the lives of patients with chronic pain conditions.

1 September 2015 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
BJBjorn Jensen
Bjorn Jensen
JCJeffrey Chen
Jeffrey Chen
TFTim Furnish
Tim Furnish
MWMark Wallace
Mark Wallace

1 November 2013 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
BIBrian M. Ilfeld
Brian M. Ilfeld
NMNisha Malhotra
Nisha Malhotra
TFTimothy J. Furnish
Timothy J. Furnish
MDMichael C. Donohue
Michael C. Donohue
SMSarah J. Madison
Sarah J. Madison
BACKGROUND:Currently available local anesthetics approved for single-injection peripheral nerve blocks have a maximum duration of <24 hours. A liposomal bupivacaine formulation (EXPAREL®, Pacira Pharmaceuticals, Inc., San Diego, CA), releasing bupivacaine over 96 hours, recently gained Food and Drug

1 January 2018 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
GLGemayel Lee
Gemayel Lee
BGBrittany Grovey
Brittany Grovey
TFTim Furnish
Tim Furnish
MWMark Wallace
Mark Wallace

1 December 2017 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
JPJohn Pang
John Pang
KTKathryn R. Tringale
Kathryn R. Tringale
VTViridiana J. Tapia
Viridiana J. Tapia
WMWilliam J. Moss
William J. Moss
MMMegan E. May
Megan E. May
JCJoseph A. Califano
Joseph A. Califano
Chronic pain is a major concern for patients with head and neck cancer (HNC), affecting up to 60% of survivors.1,2 Despite the need to effectively manage chronic pain, a recent meta-analysis3 of pain management in patients with cancer concluded that nearly half are not optimally treated. In 2013, the National Comprehensive Cancer Network (NCCN) released its first set of clinical practice guidelines in an effort to improve survivorship of patients with cancer. Pain management was 1 of 8 domains receiving specific attention in these guidelines.4